NL-OMON27865尚未招募不适用
PROSPECTIVE FASE-II TRIAL EVALUATING THE OUTCOME OF INDUCTION CHEMOTHERAPY FOLLOWED BY EXTENDED LYMPH NODE DISSECTION AND CHEMORADIATION FOR HIGH RISK INVASIVE BLADDER CANCER-CHEMORAD-TRIAL
The Netherlands Cancer Institute-Antoni van Leeuwenhoek HospitalPostbus 90203, 1006 BE, AmsterdamThe Netherlands0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Signed written informed consent
- •-Locally advanced urothelial carcinoma of the bladder (cT3-T4) or any cT-stage with cytologically or histologically proven node positive urothelial carcinoma (or positive FDG/PET-CT-scan with suspect lymph nodes, including supraregional retroperitoneal lymph nodes below the diaphragm.
排除标准
- •-Distant metastases (M+)
- •-Severe bladder symptoms (necessitating cystectomy).
研究者
相似试验
已完成
2 期
PROSPECTIVE FASE-II TRIAL EVALUATING THE OUTCOME OF INDUCTION CHEMOTHERAPY FOLLOWED BY EXTENDED LYMPH NODE DISSECTION AND CHEMORADIATION FOR HIGH RISK INVASIVE BLADDER CANCER<br>'bladder cancer' and 'high-risk muscle invasive bladder cancer'100383641000499410038365NL-OMON43780Antoni van Leeuwenhoek Ziekenhuis50
已完成
不适用
A PHASE II PROSPECTIVE TRIAL CORRELATING THE PROGRESSION FREE SURVIVAL CYP2D6 WITH ACTIVITY IN PATIENTS WITH METASTATIC BREAST CANCER TREATED WITH SINGLE AGENT TAMOXIFE-C61 Malignant neoplasm of prostateMalignant neoplasm of prostateC61PER-114-10EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG), GRUPO DE ESTUDIOS CLINICOS ONCOLOGICO DEL PERU GECOPERU,37
进行中（未招募）
1 期
PHASE II TRIAL TO EVALUATE THE EFFICACY OF OBINUTUZUMAB (RO5072759) + BENDAMUSTINE TREATMENT IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIAChronic lymphocytic leukemiaMedDRA version: 16.1 Level: LLT Classification code 10008977 Term: Chronic lymphocytic leukemia recurrent System Organ Class: 100000004864EUCTR2013-003388-79-ESRoche Farma, S.A.72
进行中（未招募）
1 期
A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma - Combination Infliximab and Sorafenib in RCCMetastatic Renal Cell Carcinoma (RCC)MedDRA version: 8.1Level: HLTClassification code 10038408Term: Renal cell carcinomasEUCTR2006-004822-97-GBThe Royal Marsden NHSF Trust51
进行中（未招募）
不适用
Proof-of-concept phase II study to evaluate the anti-tumoractivity of sorafenib along with pathological and molecularchanges in tumor samples from patientswith resectable hepatocellular carcinoma. - BIOSHAREHepatocellular carcinoma resectableMedDRA version: 12.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableEUCTR2009-018058-44-FRGERCOR